Lead Product(s) : Selonabant
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase II
Sponsor : National Institutes of Health
Deal Size : $1.9 million
Deal Type : Funding
Anebulo Pharmaceuticals Awarded NIDA Grant for Acute Cannabis-Induced Toxic Effects
Details : The funding aims to support the development of ANEB-001 (selonabant) for the potential use as an emergency treatment of acute cannabis-induced toxicities, including cannabis-induced CNS depression.
Brand Name : ANEB-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 22, 2024
Lead Product(s) : Selonabant
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase II
Sponsor : National Institutes of Health
Deal Size : $1.9 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?